Literature DB >> 10882947

The prevalence and management of onychomycosis in diabetic patients.

A K Gupta1, S Humke.   

Abstract

The incidence of diabetes mellitus is increasing throughout the world. Diabetic patients must cope with the serious complications of this condition, such as renal disease, retinopathy and the diabetic foot. To date, very few studies have examined the prevalence of onychomycosis among diabetic subjects. However, two recent studies highlight an increased incidence of onychomycosis and other superficial fungal infections in these patients. Nail and other fungal skin infections pose a greater risk in this patient population because of the possible sequelae. In addition, impaired sensation in the lower extremities can mask minor abrasions and ulcerations on a diabetic patient's foot, which may develop into serious bacterial infections and contribute to the severity of the diabetic foot. Given the potential morbidity that may result from fungal infections of the extremities, effective treatment is of paramount importance. An ideal antifungal agent should combine a broad spectrum of activity with good efficacy and a favorable safety profile.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882947

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  20 in total

1.  Uncommon fungi isolated from diabetic patients toenails with or without visible onychomycoses.

Authors:  Marisela González-Avila; Juan Vicente Gómez-Gómez; Alejandra Paula Espinosa Texis; José Luis Imbert-Palafox; Marco Antonio Becerril-Flores; José Luis Blasco
Journal:  Mycopathologia       Date:  2011-04-22       Impact factor: 2.574

2.  Onychomycosis and tinea pedis in athletes from the State of Rio Grande Do Sul (Brazil): a cross-sectional study.

Authors:  Clarice Saggin Sabadin; Sérgio Augusto Benvegnú; Mara Mary Carvalho da Fontoura; Ligia Maria Fernandes Saggin; Jane Tomimori; Olga Fischman
Journal:  Mycopathologia       Date:  2010-09-28       Impact factor: 2.574

3.  Can the use of a topical antifungal nail lacquer reduce risk for diabetic foot ulceration? Results from a randomised controlled pilot study.

Authors:  David G Armstrong; Katherine Holtz; Stephanie Wu
Journal:  Int Wound J       Date:  2005-06       Impact factor: 3.315

4.  Evaluation of an Explanted Porcine Skin Model to Investigate Infection with the Dermatophyte Trichophyton rubrum.

Authors:  Fritz Ka-Ho Ho; M Begoña Delgado-Charro; Albert Bolhuis
Journal:  Mycopathologia       Date:  2020-02-27       Impact factor: 2.574

Review 5.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Clinical retrospective analysis of long-pulsed 1064-nm Nd:YAG laser in the treatment of onychomycosis and its effect on the ultrastructure of fungus pathogen.

Authors:  Yanyun Cao; Shunming Xu; Wei Kong; Yang Xu; Hua Fang
Journal:  Lasers Med Sci       Date:  2019-07-16       Impact factor: 3.161

7.  Onychomycosis of Toenails and Post-hoc Analyses with Efinaconazole 10% Solution Once-daily Treatment: Impact of Disease Severity and Other Concomitant Associated Factors on Selection of Therapy and Therapeutic Outcomes.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2016-02

8.  Onychomycosis in Older Adults: Prevalence, Diagnosis, and Management.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Mesbah Talukder
Journal:  Drugs Aging       Date:  2022-02-01       Impact factor: 3.923

9.  Cutaneous disorders in 500 diabetic patients attending diabetic clinic.

Authors:  Shivanna Ragunatha; Bhaktavatsalam Anitha; Arun C Inamadar; Aparna Palit; Shashidhar S Devarmani
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

10.  Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review.

Authors:  Lisa Matricciani; Kerwin Talbot; Sara Jones
Journal:  J Foot Ankle Res       Date:  2011-12-04       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.